Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vilsbøll, T.
Right arrow Articles by Holst, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vilsbøll, T.
Right arrow Articles by Holst, J. J.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes 50:609-613, 2001
© 2001 by the American Diabetes Association, Inc.

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Tina Vilsbøll1,2, Thure Krarup1, Carolyn F. Deacon2, Sten Madsbad3, and Jens J. Holst2

1 Department of Internal Medicine F, Gentofte Hospital
2 Department of Medical Physiology, the Panum Institute
3 Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark

Incretin hormones importantly enhance postprandial insulin secretion but are rapidly degraded to inactive metabolites by ubiquitous dipeptidyl peptidase IV. The concentrations of the intact biologically active hormones remain largely unknown. Using newly developed assays for intact glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP), we measured plasma concentrations after a mixed breakfast meal (566 kcal) in 12 type 2 diabetic patients (age 57 years [range 49–67], BMI 31 kg/m2 [27–38], and HbA1c 9.2% [7.0–12.5]) and 12 matched healthy subjects. The patients had fasting hyperglycemia (10.7 mmol/l [8.0–14.8]) increasing to 14.6 mmol/l (11.5–21.5) 75 min after meal ingestion. Fasting levels of insulin and C-peptide were similar to those of the healthy subjects, but the postprandial responses were reduced and delayed. Fasting levels and meal responses were similar between patients and healthy subjects for total GIP (intact + metabolite) as well as intact GIP, except for a small decrease in the patients at 120 min; integrated areas for intact hormone (area under the curve [AUC]INT) averaged 52 ± 4% (for patients) versus 56 ± 3% (for control subjects) of total hormone AUC (AUCTOT). AUCINT for GLP-1 averaged 48 ± 2% (for patients) versus 51 ± 5% (for control subjects) of AUCTOT. AUCTOT for GLP-1 as well as AUCINT tended to be reduced in the patients (P = 0.2 and 0.07, respectively); but the profile of the intact GLP-1 response was characterized by a small early rise (30–45 min) and a significantly reduced late phase (75–150 min) (P < 0.02). The measurement of intact incretin hormones revealed that total as well as intact GIP responses were minimally decreased in patients with type 2 diabetes, whereas the late intact GLP-1 response was strongly reduced, supporting the hypothesis that an impaired function of GLP-1 as a transmitter in the enteroinsular axis contributes to the inappropriate insulin secretion in type 2 diabetes.

Abbreviations: AUC, area under the curve; DPP-IV, dipeptidyl peptidase IV; GIP, glucose-dependent insulinotropic polypeptide; GLP, glucagon-like peptide; RIA, radioimmunoassay


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
K. Vollmer, J. J. Holst, B. Baller, M. Ellrichmann, M. A. Nauck, W. E. Schmidt, and J. J. Meier
Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance
Diabetes, March 1, 2008; 57(3): 678 - 687.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. P. Choukem and J.-F. Gautier
Comment on: Knop et al. (2007) Reduced Incretin Effect in Type 2 Diabetes: Cause or Consequence of the Diabetic State? Diabetes 56:1951 1959
Diabetes, January 1, 2008; 57(1): e1 - e1.
[Full Text] [PDF]

Home page
 DiabetesHome page
F. K. Knop, T. Vilsboll, S. Madsbad, T. Krarup, and J. J. Holst
Response to Comment on: Knop et al. (2007) Reduced Incretin Effect in Type 2 Diabetes: Cause or Consequence of the Diabetic State? Diabetes 56:1951 1959
Diabetes, January 1, 2008; 57(1): e2 - e3.
[Full Text] [PDF]

Home page
 DiabetesHome page
S. Pereira, E. B. Marliss, J. A. Morais, S. Chevalier, and R. Gougeon
Insulin Resistance of Protein Metabolism in Type 2 Diabetes
Diabetes, January 1, 2008; 57(1): 56 - 63.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
J. J. Holst
The Physiology of Glucagon-like Peptide 1
Physiol Rev, October 1, 2007; 87(4): 1409 - 1439.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. P. Vahl, M. Tauchi, T. S. Durler, E. E. Elfers, T. M. Fernandes, R. D. Bitner, K. S. Ellis, S. C. Woods, R. J. Seeley, J. P. Herman, et al.
Glucagon-Like Peptide-1 (GLP-1) Receptors Expressed on Nerve Terminals in the Portal Vein Mediate the Effects of Endogenous GLP-1 on Glucose Tolerance in Rats
Endocrinology, October 1, 2007; 148(10): 4965 - 4973.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
Y.-L. He, R. Sabo, G. Sunkara, M.-N. Bizot, G.-J. Riviere, S. Leon, M. Ligueros-Saylan, W. P. Dole, and D. Howard
Evaluation of Pharmacokinetic Interactions Between Vildagliptin and Digoxin in Healthy Volunteers
J. Clin. Pharmacol., August 1, 2007; 47(8): 998 - 1004.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
F. K. Knop, T. Vilsboll, P. V. Hojberg, S. Larsen, S. Madsbad, A. Volund, J. J. Holst, and T. Krarup
Reduced Incretin Effect in Type 2 Diabetes: Cause or Consequence of the Diabetic State?
Diabetes, August 1, 2007; 56(8): 1951 - 1959.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Iakoubov, A. Izzo, A. Yeung, C. I. Whiteside, and P. L. Brubaker
Protein Kinase C{zeta} Is Required for Oleic Acid-Induced Secretion of Glucagon-Like Peptide-1 by Intestinal Endocrine L Cells
Endocrinology, March 1, 2007; 148(3): 1089 - 1098.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
F. K. Knop, T. Vilsboll, S. Larsen, P. V. Hojberg, A. Volund, S. Madsbad, J. J. Holst, and T. Krarup
Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution
Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E324 - E330.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
J. Ryskjaer, C. F Deacon, R. D Carr, T. Krarup, S. Madsbad, J. Holst, and T. Vilsboll
Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake
Eur. J. Endocrinol., September 1, 2006; 155(3): 485 - 493.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. A Miller and E. L St. Onge
Sitagliptin: A Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes
Ann. Pharmacother., July 1, 2006; 40(7): 1336 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
D. F. Kruger, C. L. Martin, and C. E. Sadler
New insights into glucose regulation.
The Diabetes Educator, March 1, 2006; 32(2): 221 - 228.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. J. Theodorakis, O. Carlson, S. Michopoulos, M. E. Doyle, M. Juhaszova, K. Petraki, and J. M. Egan
Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
Am J Physiol Endocrinol Metab, March 1, 2006; 290(3): E550 - E559.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
D. J. Drucker
Incretin-based therapies: a clinical need filled by unique metabolic effects.
The Diabetes Educator, March 1, 2006; 32(2 Suppl): 65S - 71S.
[Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
D. J. Drucker
The evidence for achieving glycemic control with incretin mimetics.
The Diabetes Educator, March 1, 2006; 32(2 Suppl): 72S - 81S.
[Full Text] [PDF]

Home page
 GutHome page
J Schirra, M Nicolaus, R Roggel, M Katschinski, M Storr, H J Woerle, and B Goke
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans
Gut, February 1, 2006; 55(2): 243 - 251.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
R. Chaikomin, S. Doran, K. L. Jones, C. Feinle-Bisset, D. O'Donovan, C. K. Rayner, and M. Horowitz
Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects
Am J Physiol Endocrinol Metab, September 1, 2005; 289(3): E504 - E507.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. H. Schou, K. Pilgaard, T. Vilsboll, C. B. Jensen, C. F. Deacon, J. J. Holst, A. Volund, S. Madsbad, and A. A. Vaag
Normal Secretion and Action of the Gut Incretin Hormones Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Young Men with Low Birth Weight
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4912 - 4919.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
B D Green, N Irwin, V A Gault, C J Bailey, F P M O'Harte, and P R Flatt
Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice
J. Endocrinol., May 1, 2005; 185(2): 307 - 317.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Ferrannini, A. Gastaldelli, Y. Miyazaki, M. Matsuda, A. Mari, and R. A. DeFronzo
{beta}-Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 493 - 500.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. V Joy, P. T Rodgers, and A. C Scates
Incretin Mimetics as Emerging Treatments for Type 2 Diabetes
Ann. Pharmacother., January 1, 2005; 39(1): 110 - 118.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. A. Nauck, B. Baller, and J. J. Meier
Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes
Diabetes, December 1, 2004; 53(suppl_3): S190 - S196.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. J. Holst and C. Orskov
The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism
Diabetes, December 1, 2004; 53(suppl_3): S197 - S204.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. F. Deacon
Therapeutic Strategies Based on Glucagon-Like Peptide 1
Diabetes, September 1, 2004; 53(9): 2181 - 2189.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. J. Theodorakis, O. Carlson, D. C. Muller, and J. M. Egan
Elevated Plasma Glucose-Dependent Insulinotropic Polypeptide Associates With Hyperinsulinemia in Impaired Glucose Tolerance
Diabetes Care, July 1, 2004; 27(7): 1692 - 1698.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
S. L. Aronoff, K. Berkowitz, B. Shreiner, and L. Want
Glucose Metabolism and Regulation: Beyond Insulin and Glucagon
Diabetes Spectr, July 1, 2004; 17(3): 183 - 190.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
S. Madsbad, O. Schmitz, J. Ranstam, G. Jakobsen, and D. R. Matthews
Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial
Diabetes Care, June 1, 2004; 27(6): 1335 - 1342.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
D. A. D'Alessio and T. P. Vahl
Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes
Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E882 - E890.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
T. Damci, S. Yalin, H. Balci, Z. Osar, U. Korugan, M. Ozyazar, and H. Ilkova
Orlistat Augments Postprandial Increases in Glucagon-like Peptide 1 in Obese Type 2 Diabetic Patients
Diabetes Care, May 1, 2004; 27(5): 1077 - 1080.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
K. B. Degn, C. B. Juhl, J. Sturis, G. Jakobsen, B. Brock, V. Chandramouli, J. Rungby, B. R. Landau, and O. Schmitz
One Week's Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and {alpha}- and {beta}-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes
Diabetes, May 1, 2004; 53(5): 1187 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. Hansotia, L. L. Baggio, D. Delmeire, S. A. Hinke, Y. Yamada, K. Tsukiyama, Y. Seino, J. J. Holst, F. Schuit, and D.J. Drucker
Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors
Diabetes, May 1, 2004; 53(5): 1326 - 1335.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. J. Meier, O. Goetze, J. Anstipp, D. Hagemann, J. J. Holst, W. E. Schmidt, B. Gallwitz, and M. A. Nauck
Gastric inhibitory polypeptide does not inhibit gastric emptying in humans
Am J Physiol Endocrinol Metab, April 1, 2004; 286(4): E621 - E625.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. J. Meier, M. A. Nauck, D. Kranz, J. J. Holst, C. F. Deacon, D. Gaeckler, W. E. Schmidt, and B. Gallwitz
Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects
Diabetes, March 1, 2004; 53(3): 654 - 662.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Vilsboll, F. K. Knop, T. Krarup, A. Johansen, S. Madsbad, S. Larsen, T. Hansen, O. Pedersen, and J. J. Holst
The Pathophysiology of Diabetes Involves a Defective Amplification of the Late-Phase Insulin Response to Glucose by Glucose-Dependent Insulinotropic Polypeptide--Regardless of Etiology and Phenotype
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4897 - 4903.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. J. Drucker
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Diabetes Care, October 1, 2003; 26(10): 2929 - 2940.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Vilsboll, T. Krarup, J. Sonne, S. Madsbad, A. Volund, A. G. Juul, and J. J. Holst
Incretin Secretion in Relation to Meal Size and Body Weight in Healthy Subjects and People with Type 1 and Type 2 Diabetes Mellitus
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2706 - 2713.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. Nishizawa, M. C. Moore, M. Shiota, S. M. Gustavson, W. L. Snead, D. W. Neal, and A. D. Cherrington
Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs
Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E1027 - E1036.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. P. Vahl, B. W. Paty, B. D. Fuller, R. L. Prigeon, and D. A. D'Alessio
Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on Intravenous Glucose Tolerance and Glucose-Induced Insulin Secretion in Healthy Humans
J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1772 - 1779.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
C. Thomsen, H. Storm, J. J Holst, and K. Hermansen
Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes
Am. J. Clinical Nutrition, March 1, 2003; 77(3): 605 - 611.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
K. E. Mayo, L. J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, and D. J. Drucker
International Union of Pharmacology. XXXV. The Glucagon Receptor Family
Pharmacol. Rev., March 1, 2003; 55(1): 167 - 194.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
Y. Anini and P. L. Brubaker
Role of Leptin in the Regulation of Glucagon-Like Peptide-1 Secretion
Diabetes, February 1, 2003; 52(2): 252 - 259.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Vilsboll, H. Agerso, T. Krarup, and J. J. Holst
Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects
J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 220 - 224.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. Farilla, H. Hui, C. Bertolotto, E. Kang, A. Bulotta, U. Di Mario, and R. Perfetti
Glucagon-Like Peptide-1 Promotes Islet Cell Growth and Inhibits Apoptosis in Zucker Diabetic Rats
Endocrinology, November 1, 2002; 143(11): 4397 - 4408.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
F. Reimann and F. M. Gribble
Glucose-Sensing in Glucagon-Like Peptide-1-Secreting Cells
Diabetes, September 1, 2002; 51(9): 2757 - 2763.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Barat-Houari, K. Clement, V. Vatin, C. Dina, G. Bonhomme, F. Vasseur, B. Guy-Grand, and P. Froguel
Positional Candidate Gene Analysis of Lim Domain Homeobox Gene (Isl-1) on Chromosome 5q11-q13 in a French Morbidly Obese Population Suggests Indication for Association With Type 2 Diabetes
Diabetes, May 1, 2002; 51(5): 1640 - 1643.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. B. Juhl, M. Hollingdal, J. Sturis, G. Jakobsen, H. Agerso, J. Veldhuis, N. Porksen, and O. Schmitz
Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes
Diabetes, February 1, 2002; 51(2): 424 - 429.
[Abstract] [Full Text] [PDF]

Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
G. S. Meneilly, C. H.S. McIntosh, R. A. Pederson, J. F. Habener, R. Gingerich, J. M. Egan, and D. Elahi
Glucagon-like Peptide-1 (7-37) Augments Insulin-Mediated Glucose Uptake in Elderly Patients With Diabetes
J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2001; 56(11): M681 - 685.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2001 by the American Diabetes Association.